Current Research Studies

A Prospective, Observational Study Evaluating the Real-World Experience of Givinostat in Patients with Duchenne Muscular Dystrophy

Givinostat Registry

  • Phase: Post-Approval/Marketing
  • Clinicaltrials.gov ID: NCT07127978

What is the goal of the study?

Is an observational study, that evaluate the experience of Givinostat (DUVYZAT®). Givinostat is the first non-steroidal treatment for use in patients with DMD irrespective of the specific genetic variant. It is an orally available histone deacetylase inhibitor indicated for treatment of DMD in patients aged 6 years and older. The Food and Drug Administration (FDA) approved it in March 2024.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: